Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Läsionale Therapieoptionen beim maligen Melanom

Läsionale Therapieoptionen beim maligen Melanom Leitthema Onkologe 2018 · 24:464–471 F. Kiecker ·G. Poch ·K.Farmer https://doi.org/10.1007/s00761-018-0371-6 Klinik für Dermatologie, Venerologie und Allergologie, Charité Universitätsmedizin Berlin, Berlin, Online publiziert: 11. April 2018 Deutschland © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018 Läsionale Therapieoptionen beim maligen Melanom Bei Intransitmetastasen handelt se Patienten von vielen Studien ausge- morbiditäten eine Operation als unge- es sich um kutane oder subkutane, schlossen waren. Viele regionale Thera- eignet erscheinen lassen. Es sind jedoch lymphatische Absiedelungen von pieverfahrenwiez.B.Extremitätenperfu- keine Vergleichsdaten verfügbar, die die Melanomzellen zwischen dem sion und Elektrochemotherapie sind nie Ergebnisse nach Operation mit denen Primärtumor und der regionalen direkt miteinander verglichen worden; nach nicht operativen Therapiemaßnah- Lymphknotenstation. Es ist noch auch ihr Einfluss auf die Gesamtüberle- men gegenüberstellen. nicht klar, warum bei manchen benszeit ist nicht gut untersucht. Beim Aurft eten von zahlreichen In- Melanompatienten ausschließlich transitfiliae kommen heutzutage viel frü- lokoregionäre Metastasen in her Systemtherapien zum Einsatz, de- In den meisten Melanom- den Lymphknoten, bei anderen ren Effektivität den früher standardmä- leitlinien wird kein stan- nur auf der Intransitstrecke und ßig eingesetzten Chemotherapien deut- dardisiertes Vorgehen bei bei wiederum anderen beide lich überlegen ist. Dies führt auch dazu, Manifestationsformen auftreten. Intransitmetastasen angegeben dass Amputationen ganzer Gliedmaßen http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Der Onkologe Springer Journals

Läsionale Therapieoptionen beim maligen Melanom

Kiecker, F.; Poch, G.; Farmer, K.
Der Onkologe , Volume 24 (6) – Apr 11, 2018
Download PDF
8 pages
Read Article

Loading next page...
 
/lp/springer_journal/l-sionale-therapieoptionen-beim-maligen-melanom-ybbjr2c4Si
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Medizin Verlag GmbH, ein Teil von Springer Nature
Subject
Medicine & Public Health; Oncology
ISSN
0947-8965
eISSN
1433-0415
DOI
10.1007/s00761-018-0371-6
Publisher site
See Article on Publisher Site

Abstract

Leitthema Onkologe 2018 · 24:464–471 F. Kiecker ·G. Poch ·K.Farmer https://doi.org/10.1007/s00761-018-0371-6 Klinik für Dermatologie, Venerologie und Allergologie, Charité Universitätsmedizin Berlin, Berlin, Online publiziert: 11. April 2018 Deutschland © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018 Läsionale Therapieoptionen beim maligen Melanom Bei Intransitmetastasen handelt se Patienten von vielen Studien ausge- morbiditäten eine Operation als unge- es sich um kutane oder subkutane, schlossen waren. Viele regionale Thera- eignet erscheinen lassen. Es sind jedoch lymphatische Absiedelungen von pieverfahrenwiez.B.Extremitätenperfu- keine Vergleichsdaten verfügbar, die die Melanomzellen zwischen dem sion und Elektrochemotherapie sind nie Ergebnisse nach Operation mit denen Primärtumor und der regionalen direkt miteinander verglichen worden; nach nicht operativen Therapiemaßnah- Lymphknotenstation. Es ist noch auch ihr Einfluss auf die Gesamtüberle- men gegenüberstellen. nicht klar, warum bei manchen benszeit ist nicht gut untersucht. Beim Aurft eten von zahlreichen In- Melanompatienten ausschließlich transitfiliae kommen heutzutage viel frü- lokoregionäre Metastasen in her Systemtherapien zum Einsatz, de- In den meisten Melanom- den Lymphknoten, bei anderen ren Effektivität den früher standardmä- leitlinien wird kein stan- nur auf der Intransitstrecke und ßig eingesetzten Chemotherapien deut- dardisiertes Vorgehen bei bei wiederum anderen beide lich überlegen ist. Dies führt auch dazu, Manifestationsformen auftreten. Intransitmetastasen angegeben dass Amputationen ganzer Gliedmaßen

Journal

Der Onkologe – Springer Journals

Published: Apr 11, 2018

References

  • Final version of 2009 AJCC melanoma staging and classification
    Balch, CM; Gershenwald, JE; Soong, SJ
  • Prognosis and determinants of outcome following loco-regional or distant recurrence in patients with cutaneous melanoma
    Francken, AB; Accortt, NA; Shaw, HM
  • Surgical management of melanoma: an EORTC Melanoma Group Survey
    Testori, A; Soteldo, J; Powell, B
  • Surgical treatment of melanoma: a survey of Italian hospitals
    Testori, A; Chiarion Sileni, V; Stanganelli, I
  • Alternative for the treatment of local advanced disease: electrochemotherapy, limb pefusion, limb infusion, intralesional Il2. What is the role?
    Testori, A; Intelisano, A; Verrecchia, F
  • Local and intralesional therapy of in-transit melanoma metastases
    Testori, A; Faries, MB; Thompson, JF
  • Major amputation for advanced melanoma: an epidemiological study
    Ebskov, LB
  • Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit
    Creech, O; Krementz, ET; Ryan, RF; Winblad, JN
  • Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics
    Benckhuijsen, C; Kroon, BB; Geel, AN; Wieberdink, J
  • Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions
    Wieberdink, J; Benckhuysen, C; Braat, RP
  • Optimization of isolated hyperthermic limb perfusion
    Omlor, G
  • Selective heat sensitivity of cancer cells. Biochemical and clinical studies
    Cavaliere, R; Ciocatto, EC; Giovanella, BC
  • Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma
    Clark, J; Grabs, AJ; Parsons, PG
  • The application of hyperthermia in regional chemotherapy
    Filippo, F; Anza, M; Rossi, CR
  • Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters
    Alexander, HR; Fraker, DL; Bartlett, DL
  • Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions
    Vrouenraets, BC; Klaase, JM; Kroon, BB
  • Thirty-five years of isolated limb perfusion for melanoma: indications and results
    Vrouenraets, BC; Nieweg, OE; Kroon, BB
  • Prognostic factors influencing tumor response, loco-regional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion
    Filippo, F; Giacomini, P; Rossi, CR
  • Current uses of isolated limb perfusion in the clinic and a model system for new strategies
    Eggermont, AMM; Wilt, JHW; Hagen, TLM
  • Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group
    Hafstrom, L; Rudenstam, CM; Blomquist, E
  • Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response
    Aloia, TA; Grubbs, E; Onaitis, M
  • Isolated limb perfusion for unresectable melanoma of the extremities
    Noorda, EM; Vrouenraets, BC; Nieweg, OE
  • TNF dose reduction in isolated limb perfusion
    Grunhagen, DJ; Wilt, JH; Geel, AN
  • Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advancedmelanoma and soft-tissue sarcoma
    Hayes, AJ; Neuhaus, SJ; Clark Thomas, MAJM
  • Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs
    Thompson, JF; Gianoutsos, MP
  • One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases
    Grunhagen, DJ; Brunstein, F; Graveland, WJ; Geel, AN; deWilt, JH; Eggermont, AM
  • Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
    Wilt, JH; Hagen, TL; Boeck, G
  • Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs
    Lejeune, FJ; Eggermont, AM
  • Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases
    Rossi, CR; Pasquali, S; Mocellin, S
  • Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020
    Cornett, WR; McCall, LM; Petersen, RP
  • Systemic leakage during isolated limb perfusion for melanoma
    Klaase, JM; Kroon, BB; Geel, AN
  • Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
    Hoekstra, HJ; Veerman, K; Ginkel, RJ
  • Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion
    Thompson, JF; Waugh, RC; Saw, RPM; Kam, PCA
  • Tourniquet infusion versus hyperthermic perfusion
    Karakousis, CP; Kanter, PM; Park, HC; Sharma, SD; Moore, R; Ewing, JH
  • Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy
    Roberts, MS; Wu, ZY; Siebert, GA; Anissimov, YG; Thompson, JF; Smithers, BM
  • Outcomes of isolated limb infusion for melanoma. A 14-year experience
    Kroon, HM; Moncrieff, M; Kam, PC; Thompson, JF
  • Isolated limb infusion for melanoma and sarcoma. A good alternative for isolated limb perfusion with cytotoxic drugs
    Kroon, HM; Thompson, JF; Hoekstra, HJ
  • Australian multicenter study of isolated limb infusion for melanoma
    Kroon, HM; Coventry, BJ; Giles, MH
  • Outcomes of the use of isolated limb infusion for soft tissue sarcoma of the extremity
    Moncrieff, MD; Kroon, HM; Kam, PC; Stalley, PD; Scolyer, RA; Thompson, JF
  • A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US
    Beasley, GM; Caudle, A; Petersen, RP
  • Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion
    Mian, R; Henderson, MA; Speakman, D; Finkelde, D; Ainslie, J; McKenzie, A
  • Preoperative isolated limb infusion of doxorubicin and external irradiation for limb-threatening soft tissue sarcomas
    Hegazy, MA; Kotb, SZ; Sakr, H
  • FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma
    Ryan, ER; Hill, AD; Skehan, SJ
  • Isolated limb infusion for intransit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion
    Beasley, GM; Petersen, RP; Yoo, J
  • Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma
    Lindner, P; Doubrovsky, A; Kam, PCA; Thompson, JF
  • Isolated limb infusion for malignant melanoma: predictors of response and outcome
    Barbour, AP; Thomas, J; Suffolk, J
  • Does increased experience with isolated limb infusion for advanced melanoma influence outcome? A comparison of two treatment periods at a single institution
    Huismans, AM; Kroon, HM; Kam, PCA; Thompson, JF
  • A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity
    Brady, MS; Brown, K; Patel, A; Fisher, C; Marx, W
  • Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin-D in melanoma patients
    Kroon, HM; Moncrieff, M; Kam, PC; Thompson, JF
  • Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced loco-regional melanoma
    Kroon, HM; Lin, DY; Kam, PC; Thompson, JF
  • Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma
    Kroon, HM; Lin, DY; Kam, PC; Thompson, JF
  • A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma
    Beasley, GM; McMahon, N; Sanders, G
  • Future directions in regional treatment strategies for melanoma and sarcoma
    Beasley, GM; Ross, MI; Tyler, DS
  • Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma
    Dossett Lesly, A; Ben-Shabat, I; Olofsson Bagge, R; Zager, JS
  • Novel dermatologic uses of the immune response modifier imiquimod 5 % cream
    Berman, B; Poochareon, VN; Villa, AM
  • Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis
    Turza, K; Dengel, LT; Harris, RC
  • Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma
    Damian, DL; Saw, RP; Thompson, JF
  • Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene
    Cohen, MH; Jessup, JM; Felix, EL
  • Intralesional therapy for advanced melanoma: promise and limitation
    Agarwala Sanjiv, S
  • Immunological factors which influence response to immunotherapy in malignant melanoma
    Morton, D; Eilber, F; Malmgren, R; Wood, W
  • Intralesional immunotherapy of melanoma with BCG
    Rosenberg, S; Rapp, H
  • Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases
    Mastrangelo, M; Bellet, R; Berkelhammer, J; Clark, WJ
  • Complications of BCG immunotherapy in patients with cancer
    Sparks, F; Silverstein, M; Hunt, J; Haskell, C; Pilch, Y; Morton, D
  • Intralesional interferon-alpha therapy in advanced malignant melanoma
    Wussow, P; Block, B; Hartmann, F; Deicher, H
  • Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
    Radny, P; Caroli, UM; Bauer, J
  • Phase II trial of a Toll-like receptor 9‑activating oligonucleotide in patients with metastatic melanoma
    Pashenkov, M; Goess, G; Wagner, C
  • Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
    Kaufman, HL; Kim, DW; DeRaffele, G; Mitcham, J; Coffin, RS; Kim-Schulze, S
  • Talimogene laherparepvec improves durable responce rate in patients with advanced melanoma
    Andtbacka, R; Kaufman, H; Collichio, F
  • Talimogene laherparepvec in combination with Ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma
    Puzanov, I; Milhem, MM; Minor, D
  • Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer
    Toomey, P; Kodumudi, K; Weber, A
  • Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions
    Sarnaik, A; Crago, G; Liu, H
  • Generation of an antitumor response and immunity using a small molecule drug (PV-10)
    Dees, HC; Blair, S; Harkins, J
  • Distribution and fate of rose bengal
    Bocci, V
  • On the distribution and kinetics of injected I131 rose bengal. An experimental study with special reference to the evaluation of liver function
    Meurman, L
  • Phase 2 study of intralesional PV-10 in refractory metastatic melanoma
    Thompson, JF; Agarwala, SS; Smithers, BM
  • A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy
    Foote, MC; Burmeister, BH; Thomas, J; Smithers, BM
  • A phase 2 study of intralesional PV-10 followed by radiotherapy for localized in transit or recurrent metastatic melanoma
    Foote, MC; Burmeister, BH; Thomas, J
  • Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1
    Liu, H; Innamarato, PP; Kodumudi, K
  • T cell mediated immunity after combination therapy with intralesional PV-10 and coinhibitory blockade in a melanoma model
    Weber, AM; Liu, H; Kodumudi, KN
  • In vivo evolution of tumour cells after the generation of doublestrand DNA breaks
    Mekid, H; Tounekti, O; Spatz, A; Cemazar, M; Kebir, FZ; Mir, LM
  • Bases and rationale of the electrochemotherapy
    Mir, L
  • Electrochemotherapy: an emerging cancer treatment
    Sadadcharam, M; Soden, DM; O’Sullivan, GC
  • Electrochemotherapy: aspects of preclinical development and early clinical experience
    Larkin, JO; Collins, CG; Aarons, S
  • Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients
    Rudolf, Z; Stabuc, B; Cemazr, M
  • Bleomycin-mediated electrochemotherapy of metastatic melanoma
    Glass, LF; Pepine, ML; Fenske, NA; Jaroszeski, M; Reintgen, DS; Heller, R
  • Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin
    Heller, R; Jaroszeski, MJ; Reintgen, DS
  • Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy
    Mir, LM; Glass, LF; Sersa, G
  • Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients
    Campana, LG; Mocellin, S; Basso, M
  • Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases
    Quaglino, P; Mortera, C; Osella-Abate, S
  • Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach
    Testori, A; Tosti, G; Martinoli, C
  • Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes
    Mir, L; Gehl, J; Sersa, G
  • Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors
    Byrne, CM; Thompson, JF
  • Treatment of metastatic melanoma with electrochemotherapy
    Campana, LG; Testori, A; Mozzillo, N; Rossi, CR
  • Electrochemotherapy for treatment of locally advanced superficial cancer: results from a single institution
    Pennacchioli, E; Intelisano, A; Verrecchia, F
  • Utility of electrochemotherapy in melanoma treatment
    Testori, A; Rossi, CR; Tosti, G
  • Electrochemotherapy an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study
    Marty, M; Gregor, S; Garbay, JR
  • Treatment efficacy with electrochemotherapy: a multi-institutional prospective observational study on 376 patients with superficial tumors
    Campana, LG; Testori, A; Curatolo, P
  • Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients
    Campana, LG; Mocellin, S; Basso, M
  • Electrochemotherapy for disseminated superficial metastasesfrom malignant melanoma
    Campana, LG; Valpione, S; Mocellin, S
  • Tumour destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumour responses
    Roux, S; Bernat, C; Al-Sakere, B
  • Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vessels
    Markelc, B; Sersa, G; Cemazar, M
  • Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy
    Gerlini, G; Sestini, S; Gennaro, P; Urso, C; Pimpinelli, N; Borgognoni, L
  • Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
    Mozzillo, N; Simeone, E; Benedetto, L
  • Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis
    Heppt, MV; Eigentler, TK; Kähler, KC; Herbst, RA; Göppner, D; Gambichler, T; Ulrich, J; Dippel, E; Loquai, C; Schell, B; Schilling, B; Schäd, SG; Schultz, ES; Matheis, F; Tietze, JK; Berking, C
  • Combination of radiotherapy and immune checkpoint inhibitors
    Pilones, KA; Vanpouille-Box, C; Demaria, S

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

Sign up
for free
Start 14 day
Free Trial